AngioDynamics Q1 FY2027: Revenue Up 6.9%, Gross Margin Expands 410 bps, Cash Burn Continues
ANGO sits 22% above its 52-week low of $9.39 on elevated volume (3.3× avg).
Summary
AngioDynamics reported Q1 FY2027 revenue of $80.9M (+6.9% YoY) with gross margin up 410 bps to 59.4%, but cash fell to $34.0M amid continued operating losses and restructuring costs.
Key Events · Earnings and Guidance · ANGO
-
Q1 Revenue Beats Consensus
Net sales of $80.9M, up 6.9% YoY, slightly above the $80.5M consensus. Med Tech grew 13.2% to $39.9M, driven by Auryon (+$2.4M), NanoKnife (+$1.9M), and thrombus management products.
-
Gross Margin Expansion
Total gross margin improved 410 bps to 59.4%. Med Tech margin rose 400 bps to 66.2%; Med Device margin rose 340 bps to 52.7%. Tariff refunds of $1.2M and third-party manufacturing transitions contributed.
-
Cash Position Declines
Cash fell to $34.0M from $53.9M at May 31, 2026. Operating activities used $15.3M, and investing activities used $3.1M, including $2.8M for Auryon placement units.
-
CEO Transition Costs
The quarter included $0.8M in CEO retirement and transition expenses. Eric Honroth becomes President and CEO effective November 2, 2026, succeeding Jim Clemmer.
Analysis · ANGO · Industrial Applications And Services
AngioDynamics delivered Q1 FY2027 revenue of $80.9M, up 6.9% year-over-year, with Med Tech growing 13.2% and gross margin expanding 410 basis points to 59.4%. The net loss narrowed to $7.1M from $10.9M a year ago. However, cash declined to $34.0M from $53.9M at fiscal year-end, driven by $15.3M in operating cash burn and $2.8M in Auryon placement unit investments. The company maintains a $25M revolving credit facility with no amounts drawn, and management states current cash provides sufficient liquidity for at least 12 months. The quarter also reflects $0.8M in CEO transition costs as Eric Honroth prepares to succeed Jim Clemmer on November 2, 2026.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 28.5% of the 1688 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANGO was trading at $11.43 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $480.7M. The 52-week trading range was $9.39 to $16.29. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.